Chemokine Receptor Studies: Defining the Dynamics of the Chemosynapse

趋化因子受体研究:定义趋化突触的动力学

基本信息

  • 批准号:
    7915941
  • 负责人:
  • 金额:
    $ 21.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose to test the hypothesis that when ligand binds chemokine receptors, a "dynamic chemosynapse" forms, comprised of receptor and adaptor proteins that serve to enable polarization, activation, amplification, and oscillation of small GTPases and kinases involved in organization of the actin cytoskeleton, and chemotaxis. Moreover, we propose that interference of chemokine receptor association with these adaptors will ablate CXCR2- and CXCR4-mediated chemotaxis, intravasation, extravasation, and metastasis. There are three specific aims. I) To test the hypothesis that a major role of AP-2 in mediating CXCR2/CXCR4 chemotaxis and metastasis is to orchestrate polarization and amplification of intracellular signals. We will separately interfere with AP-2 mediated receptor trafficking versus polarization of intracellular signals to distinguish the importance of these two functions of AP-2 in CXCR2/CXCR4 mediated chemotaxis and metastasis. 2) To characterize the role of IQGAP1 and VASP in linking the CXCR2 and CXCR4 chemosynapse to the actin cytoskeleton. We will characterize the interacting domains of IQGAP1 and VASP with CXCR2 and CXCR4 and determine the effects of altering these interactions on the functional responses to chemokine (including extravasation, intravasation, metastasis) of leukocytes, endothelial cells and breast cancer cells. 3) To test the hypothesis that Src-family kinase activation at the CXCR2 and CXCR4 `chemosynapse' drives chemotaxis that is Dock2 dependent and largely PI3K independent. We will determine the role of the Src-p130Cas-CrkL-Dock2 pathway in PI3K independent CXC2/CXCR4 chemotaxis. We will study these processes in dHL-60, dU937, HMEC-1 CXCR2 expressing cells and in the breast cancer cell lines naturally expressing CXCR4 (highly invasive MDA-MB-231, DU4475, BT-549 and non-invasive MCF-7, MDA-MB- 453 and MCF-10A cells). Microfluidic devices and real time intravital microscopy using 2 photon imaging will be used to track chemotaxis in vitro and intravasation/extravasation /metastasis in vivo, respectively. Characterization of the functional significance of this interaction between chemokine receptors and adaptor proteins that comprise the chemosynapse will unveil important new therapeutic targets for the treatment of malignancies. Characterization of the mechanism for PI3K independent chemotaxis will provide valuable information for design of therapies for sepsis, arthritis, and metastasis. PUBLIC HEALTH RELEVANCE: This study aims to test the hypothesis that receptors involved in regulating the motility of immune cells and tumor cells must interact with a number of proteins in the cytoplasm of the cell to stimulate proper organization of the cytoskeleton. In this study we propose to disrupt these protein/protein interactions to develop a new way of blocking tumor cell metastasis and chronic inflammation. We also will interrupt specific intracellular signals initiated by these protein/protein interactions to point the way to new targets for drug therapy for chronic inflammation and metastasis.
DESCRIPTION (provided by applicant): We propose to test the hypothesis that when ligand binds chemokine receptors, a "dynamic chemosynapse" forms, comprised of receptor and adaptor proteins that serve to enable polarization, activation, amplification, and oscillation of small GTPases and kinases involved in organization of the actin cytoskeleton, and chemotaxis.此外,我们提出,趋化因子受体缔合与这些衔接子的干扰将消除CXCR2-和CXCR4介导的趋化性,侵入,渗出和转移。有三个特定的目标。 i)检验以下假设:AP-2在介导CXCR2/CXCR4趋化性和转移中的主要作用是调整细胞内信号的极化和扩增。我们将分别干扰AP-2介导的受体运输与细胞内信号的极化,以区分AP-2在CXCR2/CXCR4介导的趋化性趋化性和转移中的重要性。 2)表征IQGAP1和VASP在将CXCR2和CXCR4化学共生与肌动蛋白细胞骨架联系起来的作用。我们将表征IQGAP1和VASP与CXCR2和CXCR4的相互作用结构域,并确定这些相互作用对白细胞,内皮细胞和乳腺癌细胞的趋化因子(包括渗出,插入,插入,转移)的功能反应的影响。 3)检验以下假设:CXCR2和CXCR4“ Chemosynapse”在CXCR2上的激活驱动趋化性趋化性趋化趋化性,该趋化性依赖于DOCK2,并且很大程度上是PI3K独立的。我们将确定SRC-P130CAS-CRKL-DOCK2途径在PI3K独立CXC2/CXCR4趋化性中的作用。我们将在DHL-60,DU937,HMEC-1 CXCR2表达细胞以及自然表达CXCR4的乳腺癌细胞系中研究这些过程(高度入侵的MDA-MB-231,DU4475,BT-549,BT-549和非侵入性MCF-7,MCF-7,MDA-MB-4-453和MCF-10A细胞)。使用2个光子成像的微流体设备和实时插入式显微镜将分别用于体外和静脉内伸入 /外内部 /转移的体内趋化性。趋化因子受体和衔接蛋白之间这种相互作用的功能意义的表征,包括化学无吸管将公布重要的新治疗靶标,以治疗恶性肿瘤。 PI3K独立趋化性机制的表征将为败血症,关节炎和转移的疗法设计提供有价值的信息。公共卫生相关性:本研究旨在检验以下假设:调节免疫细胞和肿瘤细胞运动的受体必须与细胞细胞质中的许多蛋白质相互作用,以刺激细胞骨架的适当组织。在这项研究中,我们建议破坏这些蛋白质/蛋白质相互作用,以开发一种阻断肿瘤细胞转移和慢性炎症的新方法。我们还将中断由这些蛋白质/蛋白质相互作用引发的特定特异性细胞内信号,以指向针对慢性炎症和转移药物治疗的新靶标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ann Richmond其他文献

Ann Richmond的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ann Richmond', 18)}}的其他基金

BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
  • 批准号:
    10618231
  • 财政年份:
    2020
  • 资助金额:
    $ 21.94万
  • 项目类别:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
  • 批准号:
    10454101
  • 财政年份:
    2020
  • 资助金额:
    $ 21.94万
  • 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
  • 批准号:
    10305634
  • 财政年份:
    2019
  • 资助金额:
    $ 21.94万
  • 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
  • 批准号:
    9916443
  • 财政年份:
    2019
  • 资助金额:
    $ 21.94万
  • 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
  • 批准号:
    10531596
  • 财政年份:
    2019
  • 资助金额:
    $ 21.94万
  • 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
  • 批准号:
    10609814
  • 财政年份:
    2013
  • 资助金额:
    $ 21.94万
  • 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
  • 批准号:
    10369756
  • 财政年份:
    2013
  • 资助金额:
    $ 21.94万
  • 项目类别:
Modeling New Therapeutic Approaches for Malignant Melanoma
模拟恶性黑色素瘤的新治疗方法
  • 批准号:
    8817140
  • 财政年份:
    2013
  • 资助金额:
    $ 21.94万
  • 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
  • 批准号:
    10265337
  • 财政年份:
    2013
  • 资助金额:
    $ 21.94万
  • 项目类别:
Modeling New Therapeutic Approaches for Malignant Melanoma
模拟恶性黑色素瘤的新治疗方法
  • 批准号:
    8633274
  • 财政年份:
    2013
  • 资助金额:
    $ 21.94万
  • 项目类别:

相似海外基金

Guidance of pulmonary fibroblast migration during alveolar septal formation
肺泡间隔形成过程中肺成纤维细胞迁移的指导
  • 批准号:
    9551787
  • 财政年份:
    2009
  • 资助金额:
    $ 21.94万
  • 项目类别:
Guidance of pulmonary fibroblast migration during alveolar septal formation
肺泡间隔形成过程中肺成纤维细胞迁移的指导
  • 批准号:
    10045550
  • 财政年份:
    2009
  • 资助金额:
    $ 21.94万
  • 项目类别:
Guidance of pulmonary fibroblast migration during alveolar septal formation
肺泡间隔形成过程中肺成纤维细胞迁移的指导
  • 批准号:
    10291813
  • 财政年份:
    2009
  • 资助金额:
    $ 21.94万
  • 项目类别:
Regulation of Osteoclast Function : Role of the Cbl-PI3K Complex
破骨细胞功能的调节:Cbl-PI3K 复合物的作用
  • 批准号:
    8270388
  • 财政年份:
    2008
  • 资助金额:
    $ 21.94万
  • 项目类别:
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
肝细胞癌和丙型肝炎:E2 分子机制
  • 批准号:
    7628592
  • 财政年份:
    2008
  • 资助金额:
    $ 21.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了